Clofarabine
- Generic Name
- Clofarabine
- Brand Names
- Clolar, Evoltra
- Drug Type
- Small Molecule
- Chemical Formula
- C10H11ClFN5O3
- CAS Number
- 123318-82-1
- Unique Ingredient Identifier
- 762RDY0Y2H
- Background
Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other ...
- Indication
For the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphocytic (lymphoblastic) leukemia after at least two prior regimens. It is designated as an orphan drug by the FDA for this use.
- Associated Conditions
- Refractory Acute Lymphoblastic Leukemia (ALL), Refractory Acute Myeloid Leukemia (AML), Relapsed Acute Lymphoblastic Leukemia (ALL), Refractory Langerhans cell histiocytosis
- Associated Therapies
- -
Study of Clofarabine and Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation (HCT)
- First Posted Date
- 2018-08-01
- Last Posted Date
- 2021-10-04
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 30
- Registration Number
- NCT03609814
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Post Transplant Cyclophosphamide (PTCY) as Sole Graft Versus Host Disease (GVHD) Prophylaxis for Matched Allotransplant: CYRIC
- First Posted Date
- 2017-08-28
- Last Posted Date
- 2022-07-15
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 47
- Registration Number
- NCT03263767
- Locations
- 🇫🇷
Nantes Uh, Nantes, France
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- Conditions
- Recurrent Acute Lymphoblastic LeukemiaRecurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Adult Lymphoblastic LymphomaRecurrent Burkitt LeukemiaRecurrent Burkitt LymphomaRecurrent Childhood Lymphoblastic LymphomaRefractory Burkitt LeukemiaRefractory Lymphoblastic LymphomaRefractory Acute Lymphoblastic LeukemiaRefractory Burkitt Lymphoma
- Interventions
- First Posted Date
- 2017-05-02
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 42
- Registration Number
- NCT03136146
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
- Conditions
- Interventions
- Drug: PrednisoneDrug: VincristineDrug: DaunorubicinDrug: PegaspargaseDrug: Erwinase®Drug: CyclophosphamideDrug: CytarabineDrug: MercaptopurineDrug: DasatinibDrug: MethotrexateDrug: BlinatumomabDrug: DexamethasoneDrug: RuxolitinibDrug: ThioguanineDrug: BortezomibDrug: Asparaginase Erwinia chrysanthemi (recombinant)-rywnDrug: Calaspargase PegolDrug: DoxorubicinDrug: EtoposideDrug: NelarabineDrug: ClofarabineDrug: VorinostatDrug: Idarubicin
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 790
- Registration Number
- NCT03117751
- Locations
- 🇺🇸
Children's Hospital of Michigan, Detroit, Michigan, United States
🇺🇸St. Jude Affiliate Clinic - Novant Health Hemby Children's Hospital, Charlotte, North Carolina, United States
🇦🇺The Royal Children's Hospital Melbourne, Parkville, Victoria, Australia
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
- Conditions
- Acute LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeLangerhans Cell HistiocytosisAcute Biphenotypic LeukemiaAcute Lymphoblastic LeukemiaChronic Myelomonocytic LeukemiaNon-Hodgkin LymphomaRecurrent Hodgkin LymphomaTherapy-Related Myelodysplastic SyndromeAcute Myeloid Leukemia
- Interventions
- First Posted Date
- 2017-03-30
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT03096782
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
- Conditions
- Interventions
- Drug: CyclophosphamideDrug: ClofarabineDrug: CytarabineDrug: Daunorubicin HydrochlorideDrug: DasatinibDrug: DexamethasoneOther: Laboratory Biomarker AnalysisDrug: Doxorubicin HydrochlorideDrug: EtoposideDrug: Hydrocortisone Sodium SuccinateDrug: Leucovorin CalciumDrug: MercaptopurineDrug: MethotrexateDrug: PegaspargaseRadiation: Radiation TherapyDrug: PrednisoneDrug: ThioguanineDrug: Vincristine Sulfate
- First Posted Date
- 2016-08-30
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 5949
- Registration Number
- NCT02883049
- Locations
- 🇺🇸
Nemours Children's Hospital, Orlando, Florida, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
🇺🇸Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
Personalized NK Cell Therapy in CBT
- Conditions
- Acute Myeloid Leukemia With Myelodysplasia-Related ChangesAcute Lymphoblastic LeukemiaISS Stage II Plasma Cell MyelomaAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Biphenotypic LeukemiaB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1Chemotherapy-Related LeukemiaHigh Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsISS Stage III Plasma Cell MyelomaChronic Myelomonocytic Leukemia
- Interventions
- Biological: Allogeneic Natural Killer Cell Line NK-92Biological: Anti-Thymocyte GlobulinDrug: BusulfanDrug: CyclophosphamideDrug: ClofarabineDrug: Fludarabine PhosphateDrug: MelphalanOther: Laboratory Biomarker AnalysisBiological: RituximabRadiation: Total-Body IrradiationProcedure: Umbilical Cord Blood Transplantation
- First Posted Date
- 2016-04-05
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT02727803
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Clofarabine in Chinese Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia
- First Posted Date
- 2015-09-09
- Last Posted Date
- 2015-09-09
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 44
- Registration Number
- NCT02544789
- Locations
- 🇨🇳
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
🇨🇳Department of Pediatrics, Peking University People's Hospital, Beijing, China
🇨🇳The First Hospital of China Medical University, Shenyang, China
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2015-08-10
- Last Posted Date
- 2019-04-03
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 3
- Registration Number
- NCT02518750
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)
- First Posted Date
- 2015-05-12
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT02441803
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.